| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Alcon Research |
| Information provided by: | Alcon Research |
| ClinicalTrials.gov Identifier: | NCT00061503 |
Purpose
The primary objective of this study is to describe the effect of TRAVATAN 0.004% Ophthalmic Solution on aqueous humor dynamics in subjects with a clinical diagnosis of open angle glaucoma (OAG) or ocular hypertension (OHT).
| Condition | Intervention | Phase |
|
Glaucoma Ocular Hypertension |
Drug: Travoprost |
Phase IV |
| Genetics Home Reference related topics: | early-onset glaucoma |
| MedlinePlus related topics: | Glaucoma High Blood Pressure |
| Drug Information available for: | Travoprost |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
| Official Title: | A Double-Masked, Placebo-Controlled, Paired Comparison Study of the Mechanism of Action of TRAVATAN 0.004% in Subjects With Glaucoma or Ocular Hypertension |
Eligibility
| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Contacts and Locations More Information
| Study ID Numbers: | C-01-55 |
| First Received: | May 28, 2003 |
| Last Updated: | August 4, 2008 |
| ClinicalTrials.gov Identifier: | NCT00061503 |
| Health Authority: | United States: Food and Drug Administration |
|
|
|
|
|
